COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
26 hedge funds and large institutions have $10.6M invested in COSCIENS Biopharma Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 2 reducing their positions, and 6 closing their positions.
450% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 2
187% more call options, than puts
Call options by funds: $402K | Put options by funds: $140K
42% more capital invested
Capital invested by funds: $7.48M → $10.6M (+$3.12M)
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
8% more funds holding
Funds holding: 24 → 26 (+2)
0.02% less ownership
Funds ownership: 0.15% → 0.14% (-0.02%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$861K |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$664K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$475K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$355K |
| 5 |
Renaissance Technologies
New York
|
+$299K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$2.42M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$987K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$326K |
| 4 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$74K |
| 5 |
Jane Street
New York
|
-$30K |
CSCI Hedge Fund Activity: Q1 2019 in Review
26 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q1 2019, worth a combined $10.6M — up 42% from $7.48M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CSCI positions and 6 closed out — a net gain of 2 holders — while 11 added to existing stakes and 2 trimmed.
The largest buyer was AJO LP, opening a new position worth an estimated $861K. The largest seller was J. Goldman & Co, cutting an estimated $2.42M.
- 26 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q1 2019, up from 24 in Q4 2018.
- Funds reported $10.6M of COSCIENS Biopharma Inc. Common Stock stock for Q1 2019, up 42% quarter-over-quarter.
- 8 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q1 2019 and 6 closed out, a net change of +2 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q1 2019 was AJO LP, an estimated $861K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q1 2019 was J. Goldman & Co, an estimated $2.42M sold.
Based on aggregated 13F filings for Q1 2019.